Abstract
is 97.9%, CR-HGD/CA is 93.8% and CR-BE is 70.8%. Average time in remission is 47.2 months. Patients with recurrent HGD/IMC were treated with repeat EMR. In the patient with recurrent IMC, the neoplasia was buried under squamous on the EMR specimen. Eleven patients died during study period, all from unrelated causes. Conclusion: Our nine-year experience demonstrates that CBE-EMR is an effective and safe modality to treat BE with HGD and IMC. The most commonly encountered complication of stenosis was shown to be amenable to endoscopic treatment. A 2% of perforation underscores the need for available surgical back up. Subsquamous glands may be a source of neoplastic recurrence but follow-up in this cohort is ongoing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
